Estudo randomizado | Escore baseado em painel genético para avaliar o benefício da quimioterapia para o câncer de mama com nódulo positivo.

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário no Twitter

Among postmenopausal women with HR–positive, HER2-negative breast cancer, 1-3 positive lymph nodes, and a 21-gene recurrence score of 25 or lower, 5-year invasive disease–free survival was similar whether they received endocrine or chemoendocrine therapy. https://t.co/aZLXBvSHHl pic.twitter.com/EBVnMkGHx4

— NEJM (@NEJM) December 2, 2021